Evidence map›Paper›PMID 33138305›Full record

ReviewJournal of clinical medicine2020

Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy.

Erika Grossrubatscher, Giuseppe Fanciulli, Luca Pes, Franz Sesti, Carlotta Dolci, Federica de Cicco, Annamaria Colao, Antongiulio Faggiano, Nike Group

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Expanding the therapeutic horizon ofNagoya journal of medical science · 2025
    Review
  6. Observational
  7. Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  8. Medullary Thyroid Carcinoma: Imaging.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  9. Review
  10. Review
  11. [European journal of nuclear medicine and molecular imaging · 2023
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis.Therapeutic advances in endocrinology and metabolism · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Erika GrossrubatscherEndocrine Unit, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
Giuseppe FanciulliNET Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari-Endocrine Unit, AOU Sassari, 07100 Sassari, Italy.ORCID 0000-0002-8367-5649
Luca PesEndocrine Clinic, Policlinico Sassarese, 07100 Sassari, Italy.
Franz SestiDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-3850-627X
Carlotta DolciNuclear Medicine Unit, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
Federica de CiccoDepartment of Clinical Medicine and Surgery, Endocrinology Unit, University Federico II, 80131 Naples, Italy.
Annamaria ColaoDepartment of Clinical Medicine and Surgery, Endocrinology Unit, University Federico II, 80131 Naples, Italy.
Antongiulio FaggianoDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-9324-3946
Nike Group
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITFederico II University Hospital · ITSapienza University of Rome · ITUniversity of Sassari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective treatment options in advanced/progressive/metastatic medullary thyroid carcinoma (MTC) are currently limited. As in other neuroendocrine neoplasms (NENs), peptide receptor radionuclide therapy (PRRT) has been used as a therapeutic option in MTC. To date, however, there are no published reviews dealing with PRRT approaches. We performed an in-depth narrative review on the studies published in this field and collected information on registered clinical trials related to this topic. We identified 19 published studies, collectively involving more than 200 patients with MTC, and four registered clinical trials. Most cases of MTC were treated with PRRT with somatostatin analogues (SSAs) radiolabelled with 90 yttrium (90Y) and 177 lutetium (177Lu). These radiopharmaceuticals show efficacy in the treatment of patients with MTC, with a favourable radiological response (stable disease, partial response or complete response) in more than 60% of cases, coupled with low toxicity. As MTC specifically also expresses cholecystokinin receptors (CCK2Rs), PRRT with this target has also been tried, and some randomised trials are ongoing. Overall, PRRT seems to have an effective role and might be considered in the therapeutic strategy of advanced/progressive/metastatic MTC.

Indexed as

medullary thyroid carcinomaneuroendocrine neoplasmpeptide receptor radionuclide therapysomatostatin analogues

Identifiers

PMID33138305
PMCPMC7693147
OpenAlexW3095755647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.